Connection

Robert Harrington to Angina, Unstable

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about Angina, Unstable.
Robert Harrington
Connection Strength
2.262
Angina, Unstable
  1. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. J Interv Cardiol. 2007 Oct; 20(5):299-306.
    View in: PubMed
    Score: 0.291
  2. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May; 5(3):401-12.
    View in: PubMed
    Score: 0.283
  3. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006 Feb 21; 47(4):809-16.
    View in: PubMed
    Score: 0.259
  4. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2002 Jan 22; 105(3):322-7.
    View in: PubMed
    Score: 0.196
  5. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.
    View in: PubMed
    Score: 0.117
  6. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol. 2007 May 15; 99(10):1389-93.
    View in: PubMed
    Score: 0.070
  7. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006 Oct 09; 166(18):2027-34.
    View in: PubMed
    Score: 0.068
  8. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2006 Jun; 151(6):1205-13.
    View in: PubMed
    Score: 0.066
  9. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA. 2006 Apr 26; 295(16):1912-20.
    View in: PubMed
    Score: 0.066
  10. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006 Apr 10; 166(7):806-11.
    View in: PubMed
    Score: 0.066
  11. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. Am Heart J. 2006 Jan; 151(1):16-24.
    View in: PubMed
    Score: 0.065
  12. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2005 Sep 15; 96(6):750-5.
    View in: PubMed
    Score: 0.063
  13. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Am Heart J. 2005 Jun; 149(6):994-1002.
    View in: PubMed
    Score: 0.062
  14. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 03; 292(17):2096-104.
    View in: PubMed
    Score: 0.060
  15. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J. 2004 Nov; 148(5 Suppl):S34-9.
    View in: PubMed
    Score: 0.060
  16. Changing the model of care for patients with acute coronary syndromes. Am Heart J. 2003 Oct; 146(4):605-12.
    View in: PubMed
    Score: 0.055
  17. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol. 2003 Jul 15; 92(2):136-40.
    View in: PubMed
    Score: 0.054
  18. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation. 2002 Sep 17; 106(12):1470-6.
    View in: PubMed
    Score: 0.051
  19. Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. J Am Coll Cardiol. 2002 Jun 19; 39(12):1924-9.
    View in: PubMed
    Score: 0.050
  20. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002 Jan 19; 359(9302):189-98.
    View in: PubMed
    Score: 0.049
  21. Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy). Cardiology. 2002; 98(4):195-201.
    View in: PubMed
    Score: 0.049
  22. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 04 09; 382(15):1395-1407.
    View in: PubMed
    Score: 0.043
  23. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25; 365(8):699-708.
    View in: PubMed
    Score: 0.024
  24. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009 May 12; 119(18):2454-62.
    View in: PubMed
    Score: 0.020
  25. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J. 2006 Oct; 152(4):641-7.
    View in: PubMed
    Score: 0.017
  26. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004 Jul 07; 292(1):89-96.
    View in: PubMed
    Score: 0.015
  27. Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. Am Heart J. 2004 Jan; 147(1):84-90.
    View in: PubMed
    Score: 0.014
  28. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003 Nov; 15(11):611-6.
    View in: PubMed
    Score: 0.014
  29. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003 Oct; 146(4):628-34.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.